What is the primary business of McKesson Corporation as reflected in this filing?

Based on the context of a 10-Q filing for a company like McKesson, their primary business typically involves the distribution of pharmaceuticals and healthcare products, along with related services such as technology solutions for healthcare providers.

What key financial metrics should investors focus on in this report?

Investors should focus on key metrics such as revenue growth, gross profit margins, operating expenses, net income, earnings per share (EPS), and cash flow from operations. Changes in these metrics compared to prior periods, as detailed in the Statements of Operations and Cash Flows, are crucial for assessing performance.

Are there any significant risks or legal issues mentioned that could impact McKesson?

The 'Legal Proceedings' section in Part II of the filing should be reviewed for any disclosed lawsuits, investigations, or regulatory actions that could have a material financial impact on the company. Additionally, the 'Quantitative and Qualitative Disclosures about Market Risk' and MD&A sections may highlight operational or market-related risks.

What is the significance of the unaudited nature of the financial statements?

The financial statements in a 10-Q are typically unaudited. This means they have been reviewed by management but have not undergone the rigorous audit process by an independent accounting firm that is required for annual reports (10-K). While still providing a good picture of the company's financial health, investors should be aware that they are subject to fewer checks and balances than audited statements.

MCK 10-Q Quarterly Report Q3 FY2006 — Revenue, Net Income, EPS

Summary

McKesson Corporation's (MCK) third-quarter report for fiscal year 2006, ending December 30, 2005, indicates a company navigating a period of growth and operational adjustments. The report details financial performance, including revenue and profit figures, and provides management's perspective on the company's financial condition and results of operations. Investors should pay close attention to the company's revenue streams, cost management strategies, and any significant operational or legal developments that could impact future performance. Key areas of focus for investors include the company's ability to maintain its market position in pharmaceutical distribution and related services, as well as its progress in integrating any recent acquisitions or divesting non-core assets. The report also touches upon market risks, control procedures, and legal matters, all of which are critical for a comprehensive understanding of McKesson's current standing and future outlook. The financial notes and management's discussion will offer deeper insights into the underlying drivers of the reported results.

Key Highlights

1The filing covers the third quarter of McKesson's fiscal year 2006, ending December 30, 2005.
2The report includes unaudited Condensed Consolidated Financial Statements (Balance Sheets, Statements of Operations, and Cash Flows).
3Management's Discussion and Analysis (MD&A) section provides insights into the company's financial condition and results of operations.
4Quantitative and Qualitative Disclosures about Market Risk are presented, indicating awareness of and strategies for managing financial risks.
5Information on Controls and Procedures highlights the company's internal controls over financial reporting.
6Part II of the report addresses Legal Proceedings, Unregistered Sales of Equity Securities, and Issuer Repurchases of Equity Securities, providing updates on potential liabilities and capital management activities.
7The filing includes exhibits, which may contain important contractual or other material documents.

MCKESSON CORP Quarterly Report for Q3 Ended Dec 31, 2005

Summary

Key Highlights

Frequently Asked Questions